Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study

• Published in: Journal of pharmaceutical health care and sciences Vol. 8; no. 1; pp. 1 - 28
• Main Authors: Nagai, Hirofumi, Shimada, Tsutomu, Takahashi, Yoshimitsu, Nishikawa, Mikako, Tozuka, Hiroyuki, Yamamoto, Yasuto, Niwa, Osamu, Takahara, Yutaka, Fujita, Arimi, Nagase, Katsuhiko, Kasahara, Kazuo, Yano, Seiji, Sai, Yoshimichi
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 01.12.2022; BioMed Central; BMC
• Subjects: Acid-suppressing medications; Analysis; BMI; Body mass index; Cancer; Cancer therapies; Care and treatment; Drug dosages; Epidermal growth factor; Erlotinib; Gefitinib; Hepatotoxicity; Histamine; Inhibitor drugs; Liver diseases; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Medical prognosis; Mutation; Non-small cell lung cancer; Older people; Oncology, Experimental; Palliative care; Phenols; Risk factors; Targeted cancer therapy; Toxicity; Tyrosine; Japan
• ISSN: 2055-0294; 2055-0294
• DOI: 10.1186/s40780-022-00258-7

Abstract Background Gefitinib and erlotinib, are epidermal growth factor receptor tyrosine kinase inhibitors, and are currently recommended for non-small cell lung cancer stage IV in the elderly and in patients with decreased performance status in the Japanese Lung Cancer Society Guideline, but they occasionally caused severe hepatotoxicity requiring postponement or modification of treatment. However, little is known about the risk factors for hepatotoxicity in patients receiving gefitinib and erlotinib. In this study, we investigated the factors influencing hepatotoxicity in Japanese non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib monotherapy. Methods Japanese patients with NSCLC who started gefitinib or erlotinib monotherapy from January 2005 to December 2017 at Kanazawa University Hospital or Kanazawa Medical University Hospital were included in this study. Factors affecting hepatotoxicity were retrospectively investigated by multiple logistic regression analysis. Results A total of 102 patients who received gefitinib and 95 patients who received erlotinib were included in the analysis. In the gefitinib group, a body mass index (BMI) ≥ 25 was associated with an increased risk of hepatotoxicity (OR = 4.571, 95% CI = 1.486–14.056, P  = 0.008). In the erlotinib group, concomitant use of acid-suppressing medications (AS), namely proton pump inhibitors or histamine-2 receptor antagonists, was associated with a reduced risk of hepatotoxicity (OR = 0.341, 95% CI = 0.129–0.900, P  = 0.030). Conclusions BMI ≥ 25 in patients treated with gefitinib increased the risk of hepatotoxicity. In contrast, AS combination with erlotinib reduced the risk of hepatotoxicity. Thus, because different factors influence the risk of hepatotoxicity, monitoring for adverse events should take into account patient background factors and concomitant medications.